Capital Fund Management (CFM)’s PTC Therapeutics PTCT Stock Holding History

Capital Fund Management (CFM)’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.14M	Sell	13,935 -107,351	-89%	-$7.75M	0.01%	1655
2026 Q1	$8.26M	Buy	+121,286	New	+$8.59M	0.04%	640
2020 Q3	–	Sell	-27,512	Closed	-$1.4M	–	1351
2020 Q2	$1.4M	Buy	+27,512	New	+$1.35M	0.02%	612
2020 Q1	–	Sell	-12,575	Closed	-$604K	–	1932
2019 Q4	$604K	Buy	+12,575	New	+$534K	﹤0.01%	1308
2018 Q4	–	Sell	-16,600	Closed	-$780K	–	2153
2018 Q3	$780K	Buy	+16,600	New	+$687K	﹤0.01%	1455

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Capital Fund Management (CFM)'s PTCT Position: Q2 2026 in Review

Capital Fund Management (CFM) reduced its PTC Therapeutics (PTCT) stake by 89% in Q2 2026, selling an estimated $7.75M and leaving 13,935 shares worth $1.14M. The position accounts for 0.01% of the portfolio, ranked #1655.

Capital Fund Management (CFM) first reported a position in PTCT in Q3 2018 and has held it in 5 quarters since. The position peaked at $8.26M in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Capital Fund Management (CFM) held 13,935 shares of PTC Therapeutics worth $1.14M as of Q2 2026.
Capital Fund Management (CFM) sold 107,351 PTC Therapeutics shares in Q2 2026, an estimated $7.75M.
PTC Therapeutics made up 0.01% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #1655 holding.
Capital Fund Management (CFM) first reported a position in PTC Therapeutics in Q3 2018 and has held it in 5 quarters since.
Capital Fund Management (CFM)'s PTC Therapeutics position peaked at $8.26M in Q1 2026.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.